Role of YES1 signaling in tumor therapy resistance
Hai Zhou(Yuncheng University), Helei Hou(Qingdao University), Junyan Tao(University of Pittsburgh), Xiaochun Zhang(Shanghai East Hospital), Mingjin Xu(Qingdao University), Dantong Sun(Soochow University)
Cited by 10
Related Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
|JAMA|2024|359
Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C)
|The American Journal of Gastroenterology|2020|78
miR‐152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines
|The Prostate|2013|76
miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells
|Molecular and Cellular Biochemistry|2013|69